Plotnick G D, Fisher M L, Hamilton J H, Hamilton B P
Am J Med. 1983 Apr;74(4):625-9. doi: 10.1016/0002-9343(83)91020-3.
Eighty-six hypertensive patients were treated with pindolol, a beta-adrenergic blocking drug with intrinsic sympathomimetic activity. To evaluate the interactions between beta-blockade, intrinsic sympathomimetic activity, and the level of pretreatment sympathetic activity, blood pressure, heart rate, and forced expiratory volume in one second (FEV1) were examined before and during a 15-week treatment program. The response of patients with a relatively higher pretreatment sympathetic tone reflected by a resting heart rate equal to or greater than 80 beats per minute (Group I) was compared with the response of patients with a lower pretreatment heart rate (less than 80 beats per minute) (Group II). Decreases in mean blood pressure were similar in the two groups. In patients in Group I, the net effect of pindolol was a modest decrease in heart rate and FEV1, supporting the concept that when sympathetic tone is relatively high, the beta-blocking effect is dominant. In contrast, patients in Group II showed little change in heart rate or FEV1 during pindolol treatment, reflecting a balance between the intrinsic sympathomimetic activity and beta-blocking effects of pindolol. Thus, the intrinsic sympathomimetic activity of pindolol is physiologically evident, and relative impact is dependent on the pretreatment level of sympathetic tone.
86名高血压患者接受了吲哚洛尔治疗,吲哚洛尔是一种具有内在拟交感活性的β肾上腺素能阻滞剂。为了评估β受体阻滞、内在拟交感活性与治疗前交感神经活动水平之间的相互作用,在一个为期15周的治疗方案之前和期间,对血压、心率和一秒用力呼气量(FEV1)进行了检测。将静息心率等于或大于80次/分钟(第一组)所反映的治疗前交感神经张力相对较高的患者的反应,与治疗前心率较低(小于80次/分钟)的患者(第二组)的反应进行比较。两组的平均血压下降情况相似。在第一组患者中,吲哚洛尔的净效应是心率和FEV1适度下降,这支持了交感神经张力相对较高时β受体阻滞作用占主导的观点。相比之下,第二组患者在吲哚洛尔治疗期间心率或FEV1几乎没有变化,这反映了吲哚洛尔的内在拟交感活性和β受体阻滞作用之间的平衡。因此,吲哚洛尔的内在拟交感活性在生理上是明显的,其相对影响取决于治疗前交感神经张力的水平。